Aspire Biopharma takes delivery of 2M units of BUZZ BOMB

Aspire Biopharma (ASBP) has taken delivery of two million units of its flagship caffeine supplement, BUZZ BOMB. The company said, “This delivery marks a critical milestone in Aspire’s commercialization strategy, introducing a comprehensive brand relaunch and redesigned packaging. The new aesthetic is engineered for high-impact shelf presence and digital engagement, emphasizing the product’s core advantages: nearly instant energy, precise 50mg dosing, and the convenience of sublingual absorption.”